107 related articles for article (PubMed ID: 318211)
1. Penetration of cephalothin and cefoxitin into experimental infections with Bacteroides fragilis.
O'Keefe JP; Tally FP; Barza M; Gorbach SL
Rev Infect Dis; 1979; 1(1):106-12. PubMed ID: 318211
[TBL] [Abstract][Full Text] [Related]
2. Comparison of cefoxitin and cephalothin therapy of a mixed Bacteroides fragilis and Fusobacterius necrophorum infection in mice.
Hackman AS; Wilkins TD
Antimicrob Agents Chemother; 1975 Aug; 8(2):224-5. PubMed ID: 1180547
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vivo efficiency of cefamandole and cefoxitin against Bacteroides fragilis.
Bergeron MG; Gauvreau L; Nguyen BM
Scand J Infect Dis Suppl; 1980; suppl 25():60-5. PubMed ID: 6937954
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of ceftizoxime against Bacteroides fragilis: comparison with benzylpenicillin, cephalothin, and cefoxitin.
Eley A; Greenwood D
Antimicrob Agents Chemother; 1981 Sep; 20(3):332-5. PubMed ID: 6272629
[TBL] [Abstract][Full Text] [Related]
5. [In vitro susceptibility of bacteroidaceae to cefoxitin and cephalothin (author's transl)].
Werner H; Firsching R; Krasemann C
Infection; 1977; 5(1):13-6. PubMed ID: 856727
[TBL] [Abstract][Full Text] [Related]
6. Clinical importance of cefoxitin-resistant Bacteroides fragilis isolates.
Bieluch VM; Cuchural GJ; Snydman DR; Gorbach SL; Tally FP
Diagn Microbiol Infect Dis; 1987 Jun; 7(2):119-26. PubMed ID: 3652652
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of penicillin G during experimental infection with Bacteroides fragilis.
O'Keefe JP; Tally FP; Barza M; Gorbach SL
J Infect Dis; 1978 Apr; 137(4):437-42. PubMed ID: 649987
[TBL] [Abstract][Full Text] [Related]
8. Cefoxitin and cephalothin: antimicrobial activity, human pharmacokinetics, and toxicology.
Brumfitt W; Kosmidis J; Hamilton-Miller JM; Gilchrist JN
Antimicrob Agents Chemother; 1974 Sep; 6(3):290-9. PubMed ID: 15830475
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of moxalactam in an animal model of subcutaneous abscesses: penetration into infected sites and in vivo activity against Bacteroides fragilis.
Bartlett JG; Joiner KA; Dezfulian M; Marien GJ
Rev Infect Dis; 1982; 4 Suppl():S664-9. PubMed ID: 6218580
[TBL] [Abstract][Full Text] [Related]
10. Effects of rate of infusion and probenecid on serum levels, renal excretion, and tolerance of intravenous doses of cefoxitin in humans: comparison with cephalothin.
Goodwin CS; Raftery EB; Goldberg AD; Skeggs H; Till AE; Martin CM
Antimicrob Agents Chemother; 1974 Sep; 6(3):338-46. PubMed ID: 15830485
[TBL] [Abstract][Full Text] [Related]
11. [Synergistic effect of thiamphenicol and cephalothin on Bacterioides fragilis (author's transl)].
Isono M; Aoki M; Kobayashi T; Marui T; Yamada H; Umemura A; Watanabe K; Ueno K
Jpn J Antibiot; 1981 May; 34(5):647-50. PubMed ID: 7026821
[TBL] [Abstract][Full Text] [Related]
12. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice.
Brook I
J Infect Dis; 1989 Oct; 160(4):651-6. PubMed ID: 2677161
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of 10 antimicrobial agents in experimental infections with Bacteroides fragilis.
Joiner K; Lowe B; Dzink J; Bartlett JG
J Infect Dis; 1982 Apr; 145(4):561-8. PubMed ID: 7069236
[TBL] [Abstract][Full Text] [Related]
14. The role of beta-lactamase and the permeability barrier on the activity of cephalosporins against members of the Bacteroides fragilis group.
Malouin F; Lamothe F
Can J Microbiol; 1987 Mar; 33(3):262-6. PubMed ID: 3105858
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of cephalosporins by Bacteroides.
Tally FP; O'Keefe JP; Sullivan NM; Gorbach SL
Antimicrob Agents Chemother; 1979 Nov; 16(5):565-71. PubMed ID: 525995
[TBL] [Abstract][Full Text] [Related]
16. [Microbiological evaluation of cefoxitin, a new beta-lactamase resistant cephamycin antibiotic, compared to cephalothin, cephaloridine and cefazolin].
Schassan HH; Bentfeld G
Fortschr Med; 1978 Aug; 96(30):1510-7. PubMed ID: 669547
[TBL] [Abstract][Full Text] [Related]
17. Activity of ceftizoxime and comparative compounds against Bacteroides fragilis in a mouse model of anaerobic infection.
Grappel SF; Phillips L; Actor P
J Antibiot (Tokyo); 1984 Apr; 37(4):384-8. PubMed ID: 6327593
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.
Fernández Canigia L; Castello L; Di Martino A; Greco G; Legaria MC; Litterio M; Predari SC; Rollet R; Rossetti A; Carloni G; Sarchi MI; Bianchini H
Rev Argent Microbiol; 2007; 39(3):156-60. PubMed ID: 17987852
[TBL] [Abstract][Full Text] [Related]
19. Pathogenicity of capsulate and non-capsulate members of Bacteroides fragilis and B. melaninogenicus groups in mixed infection with Escherichia coli and Streptococcus pyogenes.
Brook I
J Med Microbiol; 1988 Nov; 27(3):191-8. PubMed ID: 2903934
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor necrosis factor antibody reduces mortality in the presence of antibiotic-induced tumor necrosis factor release.
Sawyer RG; Adams RB; May AK; Rosenlof LK; Pruett TL
Arch Surg; 1993 Jan; 128(1):73-7; discussion 77-8. PubMed ID: 8418784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
